Revolution Medicines has surged 492% over one year on daraxonrasib's landmark pancreatic cancer data showing 13.2 versus 6.7 months median overall survival, fueling speculation it could be Big Pharma's next takeover target. Merck ranks as the most likely acquirer, with Keytruda's patent cliff mounting pressure and CEO Robert Davis pledging to diversify its growth portfolio. Revolution Medicines closed at $205.55 on August 11, 2026, giving it a market cap of $44.1 billion, and holds $3.94 billion in cash and marketable securities. The FDA accepted the NDA for daraxonrasib and granted Priority Voucher review, while the company's broader RAS(ON) pipeline includes elironrasib, zoldonrasib, and RMC-5127. Other potential acquirers include Bristol Myers Squibb, which already has a clinical collaboration on daraxonrasib, as well as Roche, Johnson & Johnson, and Pfizer, though no deal talks have been confirmed.
